Cargando…
Integrating Single-Cell Transcriptome and Network Analysis to Characterize the Therapeutic Response of Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by a unique BCR-ABL fusion gene. Tyrosine kinase inhibitors (TKIs) were developed to target the BCR-ABL oncoprotein, inhibiting its abnormal kinase activity. TKI treatments have significantly improved CML patient outcomes....
Autores principales: | Ma, Jialu, Pettit, Nathan, Talburt, John, Wang, Shanzhi, Weissman, Sherman M., Yang, Mary Qu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695508/ https://www.ncbi.nlm.nih.gov/pubmed/36430822 http://dx.doi.org/10.3390/ijms232214335 |
Ejemplares similares
-
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2020) -
Therapeutic use of Aldara™ in chronic myeloid leukemia
por: Marleau, Annette M, et al.
Publicado: (2007) -
Transcriptomics-Based Characterization of the Toxicity of ZnO Nanoparticles Against Chronic Myeloid Leukemia Cells
por: Alsagaby, Suliman A, et al.
Publicado: (2020) -
Single cell genomics in chronic myeloid leukemia
por: Mead, Adam J.
Publicado: (2018) -
Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia
por: Alanazi, Bader, et al.
Publicado: (2019)